Singulex is committed to improve patient health management through early disease detection.

Singulex pioneered technology that can quantitatively detect single molecules such as proteins and metabolites in complex biological samples. Our patented technology extends the dynamic range of any immunoassay by orders of magnitude, allowing drug developers to use biomarkers to measure drug efficacy, safety and disease progression. In addition, our technology is applicable to the diagnostics market, and we are actively pursuing the development of diagnostics that will change the face of medicine.

We have leveraged this unique technology to develop the Erenna™ Technology Access Program (ETAP) that allows select pharmaceutical companies to partner with us and to access our menu of biomarker immunoassays, sample analysis and just-in-time customized assay development services as well as our world-class Erenna Immunoassay System.

Latest News

03/06/08 Singulex Collaborates With Large Pharmaceutical Company in Erenna™ Technology Access Program
Opens Facility to Support European Partnerships  more >

11/27/07 Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design  more >

11/16/07 Researchers at Washington U. Use System from Biotech Singulex Inc.  more >

Events & Presentations

No upcoming events.  all events >